SCHEDULE 13G/A: NMSIC Co-Investment Fund Discloses 11.96% Stake in Exagen Inc.
Beneficial Ownership Report
NMSIC Co-Investment Fund, L.P. and its general partner, Sun Mountain Capital Partners LLC, have reported a beneficial ownership of 11.96% in Exagen Inc., holding 2,108,958 shares as of December 31, 2024.
Summary
- NMSIC Co-Investment Fund, L.P. and Sun Mountain Capital Partners LLC reported beneficial ownership of 2,108,958 shares of Exagen Inc. common stock.
- This stake represents 11.96% of Exagen Inc.'s outstanding common stock.
- The beneficial ownership percentage is calculated based on 17,637,278 shares outstanding as of November 8, 2024, as reported in Exagen's Quarterly Report on Form 10-Q for the quarter ended September 30, 2024.
- NMSIC Co-Investment Fund, L.P. directly owns the 2,108,958 shares.
- Sun Mountain Capital Partners LLC, as the general partner of NMSIC, and its controlling members (Brian Birk, Sally Coming, and Lee Rand) may be deemed to share beneficial ownership of these shares.
Sentiment
Score: 6
Explanation: The filing indicates a significant and continued institutional investment in Exagen Inc., which can be viewed positively as a sign of investor confidence, although it does not provide operational or financial performance details.
Positives
- A significant institutional investor, NMSIC Co-Investment Fund, L.P., holds a substantial 11.96% stake in Exagen Inc., which could be interpreted as a sign of confidence in the company's prospects.
Future Outlook
This document, a Schedule 13G, is a beneficial ownership report and does not contain forward-looking statements or guidance regarding the issuer's future outlook.
Industry Context
This Schedule 13G filing provides transparency regarding significant institutional ownership in Exagen Inc., which is a standard disclosure requirement for investors holding more than 5% of a company's stock. It does not provide broader industry trend analysis.
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional stake, potentially signaling confidence from a major investor.
Key Dates
| Date | Description |
|---|---|
| 2024-09-30 | End of quarter for which Exagen Inc.'s Quarterly Report on Form 10-Q was filed. |
| 2024-11-08 | Date as of which 17,637,278 shares of common stock were outstanding, used for beneficial ownership percentage calculation. |
| 2024-11-12 | Date Exagen Inc. filed its Quarterly Report on Form 10-Q for the quarter ended September 30, 2024. |
| 2024-12-31 | Date of event which requires filing of this Schedule 13G (beneficial ownership snapshot date). |
| 2025-01-29 | Signature date of the Schedule 13G filing. |
Keywords
Exagen Inc., NMSIC Co-Investment Fund, Sun Mountain Capital Partners, beneficial ownership, Schedule 13G, common stock, institutional investor, SEC filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.